Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine
- Conditions
- HIV Infections
- Registration Number
- NCT00002035
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
To compare the efficacy and safety of orally administered didanosine (ddI) with orally administered zidovudine (AZT) in the treatment of patients who exhibit increasing clinical deterioration despite treatment with AZT.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (18)
Univ of Arizona / Health Science Ctr
🇺🇸Tucson, Arizona, United States
Yale Univ Med School
🇺🇸New Haven, Connecticut, United States
G E Morey Jr
🇺🇸Fort Lauderdale, Florida, United States
VP Med Services / HHCS Research Institute Inc
🇺🇸Orlando, Florida, United States
AIDS Research Consortium of Atlanta
🇺🇸Atlanta, Georgia, United States
Edward Hines Veterans Administration Hosp
🇺🇸Hines, Illinois, United States
Univ of Kansas School of Medicine
🇺🇸Wichita, Kansas, United States
Harper Hosp
🇺🇸Detroit, Michigan, United States
Albany Med College / AIDS Treatment Ctr
🇺🇸Albany, New York, United States
Med College of Ohio
🇺🇸Toledo, Ohio, United States
Scroll for more (8 remaining)Univ of Arizona / Health Science Ctr🇺🇸Tucson, Arizona, United States